Detection of bone metastases in non-small cell lung cancer patients: Comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDGPET/CT, and bone scintigraphy

Journal of Magnetic Resonance Imaging

Volumn 30, Issue 2, 2009, Pages 298-308

  Takenaka, Daisuke ^a   Ohno, Yoshiharu ^a   Matsumoto, Keiko ^a,b   Aoyama, Nobukazu ^c   Onishi, Yumiko ^a   Koyama, Hisanobu ^a   Nogami, Munenobu ^d   Yoshikawa, Takeshi ^a   Matsumoto, Sumiaki ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Bone metastasis; Lung cancer; MRI; Nuclear medicine; PET CT; SPECT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; WHOLE BODY MRI;

AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HETEROCYCLIC COMPOUNDS; HISTORY, 18TH CENTURY; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 68049145126     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21858     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Deslauriers J. Current surgical treatment of nonsmall cell lung cancer 2001. Eur Respir J Suppl 2002;35:S61-S70.
3. Krupnick AS, Kreisel D, Hope A, Bradley J, Govindan R, Meyers B. Recent advances and future perspectives in the management of lung cancer. Curr Probl Surg 2005;42:540-610.
4. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507. (Pubitemid 36706537)
5. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004;78:1017-1023. (Pubitemid 39164825)
6. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005;128:2289-2297. (Pubitemid 41507571)
7. Nakamoto Y, Senda M, Okada T, et al. Software-based fusion of PET and CT images for suspected recurrent lung cancer. Mol Imaging Biol 2008;10:147-153.
8. Walker R, Kessar P, Blanchard R, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 2000;11:343-350. (Pubitemid 30185873)
9. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-236. (Pubitemid 32578088)
10. Barkhausen J, Quick HH, Lauenstein T, et al. Whole-body MR imaging in 30 seconds with real-time true FISP and a continuously rolling table platform: feasibility study. Radiology 2001;220:252-256. (Pubitemid 32577994)
11. Mazumdar A, Siegel MJ, Narra V, Luchtman-Jones L. Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study. AJR Am J Roentgenol 2002;179:1261-1266. (Pubitemid 35204384)
12. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004;233:139-148.
13. Ohno Y, Koyama H, Nogami M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007;26:498-509. (Pubitemid 350194569)
14. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008;248:643-654.
15. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-152. (Pubitemid 46095209)
16. Matoba M, Tonami H, Kondou T, et al. Lung carcinoma: diffusion-weighted MR imaging - preliminary evaluation with apparent diffusion coefficient. Radiology 2007;243:570-577. (Pubitemid 46649714)
17. Abdel Razek AA, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006;16:1468-1477. (Pubitemid 43871818)
18. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusionweighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006;239:122-130.
19. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004;22:275-282.
20. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622-1635. (Pubitemid 46866868)
21. Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR. Diffusion- weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 2008;18:1937-1952.
22. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003;34:575-583. (Pubitemid 36206368)
23. Brunel H, Girard N, Confort-Gouny S, et al. Fetal brain injury. J Neuroradiol 2004;31:123-137.
24. Rosenbloom M, Sullivan EV, Pfefferbaum A. Using magnetic resonance imaging and diffusion tensor imaging to assess brain damage in alcoholics. Alcohol Res Health 2003;27:146-152. (Pubitemid 39406796)
25. Lee SK, Kim DI, Kim J, et al. Diffusion-tensor MR imaging and fiber tractography: a new method of describing aberrant fiber connections in developmental CNS anomalies. Radiographics 2005;25:53-65. (Pubitemid 40186939)
26. Vanel D, Bittoun J, Tardivon A. MRI of bone metastases. Eur Radiol 1998;8:1345-1351.
27. Schweitzer ME, Levine C, Mitchell DG, Gannon FH, Gomella LG. Bull's-eyes and halos: useful MR discriminators of osseous metastases. Radiology 1993;188:249-252. (Pubitemid 23183133)
28. Nakanishi K, Kobayashi M, Nakaguchi K, et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007;6:147-155.
29. Beggs AD, Hain SF, Curran KM, O'Doherty MJ. FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging 2002;29:542-546.
30. Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007;17:939-949. (Pubitemid 46766875)
31. Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999;23:123-129. (Pubitemid 29095482)
32. Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H, Olsen S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS 1989;97:689-698. (Pubitemid 19217684)
33. Swensen SJ, Brown LR, Colby TV, Weaver AL, Midthun DE. Lung nodule enhancement at CT: prospective findings. Radiology 1996;201:447-455.
34. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37:943-948. (Pubitemid 126447126)
35. Ohno Y, Hatabu H, Takenaka D, Adachi S, Kono M, Sugimura K. Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience. Radiology 2002;224:503-511. (Pubitemid 34809134)
36. Nguyen BD. Malignant ameloblastoma with thoracic vertebral metastasis: PET/CT and MR imaging. Clin Nucl Med 2005;30:450-452.
37. Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006;36:1019-1031.
38. Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body imaging of the musculoskeletal system: the value of MR imaging. Skeletal Radiol 2007;36:1109-1119. (Pubitemid 350112367)
39. DeVita VT Jr, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 1975;35:98-110.
40. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
41. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18.
42. Li S, Sun F, Jin ZY, Xue HD, Li ML. Whole-body diffusion-weighted imaging: technical improvement and preliminary results. J Magn Reson Imaging 2007;26:1139-1144. (Pubitemid 47548180)